# Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

> **NCT02603679** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Thomas Hatschek** · enrollment: 181 (actual)

## Conditions studied

- Early-Stage Breast Carcinoma
- Estrogen Receptor Positive Tumor

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Tamoxifen + Palbociclib
- **DRUG:** Aromatase Inhibitor + Palbociclib
- **DRUG:** Goserelin + Aromatase Inhibitor + Palbociclib

## Key facts

- **NCT ID:** NCT02603679
- **Lead sponsor:** Thomas Hatschek
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-02
- **Primary completion:** 2021-07-30
- **Final completion:** 2031-12-31
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603679, "Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02603679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*